Cassava Sciences | PTIE - Operating Expenses


Cassava Sciences reported $11.17M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Abbott USD 9.31B 104M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Cara Therapeutics USD 5.94M 983K Sep/2025
Cassava Sciences USD 11.17M 2.38M Mar/2026
Eisai JPY 215.74B 15.84B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Geron USD 52.07M 6.73M Mar/2026
J&J USD 17.83B 388M Jun/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025